The D2 receptor agonist, quinpirole (0.03mg/kg, intraperitoneal [i.p.]), and 5-HT2A receptor antagonist, ketanserin (0.3mg/kg, i.p.), significantly counteracted this reduction of marble-burying behavior by trifluoperazine.
5ht2a антагонист уменьшает эффективность Трифтазина в этой модели.